Security key
00653A107
Adaptimmune Therapeutics PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY)
CUSIP: 00653A107
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / American Depositary Shares, each representing 6 Ordinary Shares
- Total 13F shares
- 1,611,452
- Total 13F value
- $41,897
- Share change
- -40,489,799
- Put/Call ratio
- 0%
- SEC-reported price per share
- $0.03
- Number of holders
- 6
- Value change
- -$5,283,488
- Number of buys
- 2
- Number of sells
- 49
- Shares outstanding
- 1,571,428,571
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
6
Top holders
6
ADAPY full security history
Ownership snapshot
Full 13F holder table
Adaptimmune Therapeutics PLC SEC filings
Adaptimmune Therapeutics PLC company facts
Broader feeds
Ownership snapshot
Top reported holders of ADAPY - Adaptimmune Therapeutics PLC - American Depositary Shares, each representing 6 Ordinary Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAILLIE GIFFORD & CO
Disclosed value leader
BAILLIE GIFFORD & CO
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
3/4/5
13F
Lead comparable stake: 4.6%
13D/G row: BAILLIE GIFFORD & CO
Showing 1-6 of 15 holder rows.
Quick read
BAILLIE GIFFORD & CO leads the comparable SEC ownership view at 4.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAILLIE GIFFORD & CO's linked filing trail.
Comparable ownership
Top 5
BAILLIE GIFFORD & CO
4.6%
EcoR1 Capital, LLC
4.2%
New Enterprise Associates 14, L.P.
0%
Long Focus Capital Management, LLC
1.2%
UBS Group AG
0.42%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO |
13D/G
|
4.6%
|
$19,146,934
70,914,570 shares
|
$0 | 31 Dec 2024 |
| EcoR1 Capital, LLC |
3/4/5
13D/G
10%+ Owner
|
4.2%
from 13D/G
|
$10,247,969
100,371,882 shares
|
— | 28 Jul 2025 |
| New Enterprise Associates 14, L.P. |
13D/G
|
0%
|
$0.4
4 shares
|
$0 | 15 Aug 2025 |
| Long Focus Capital Management, LLC |
13F
Company
|
1.2%
|
$2,415,117
18,577,821 shares
|
— | 30 Sep 2025 |
| UBS Group AG |
13F
Company
|
0.42%
|
$866,756
6,667,358 shares
|
— | 30 Sep 2025 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.26%
|
$527,032
4,054,089 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
6
Shares
1,611,452
Rows available
6
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
54
Q4 2025 holders
6
Holder diff
-48
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|